Lupin Limited has informed the Exchange regarding a press release dated Jun 14, 2021, titled "Lupin receives UK marketing authorization for Luforbec�� 100/6 μg pMDI,first branded generic alternative to Fostair�� 100/6 μg pMDI for treatmentof Asthma & COPD.".